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Abstract 
With the increasing use of abdominal imaging, 
cystic lesions of the pancreas are being more frequently 
detected.  These lesions may carry a significant 
premalignant potential.  Current guidelines recommend 
that mucinous cystic neoplasms, solid pseudopapillary 
neoplasms, main duct-intraductal papillary mucinous 
neoplasms and branch duct-intraductal papillary 
mucinous neoplasms (DB-IPMN) with "high-risk 
stigmata" for malignancy should be resected while 
asymptomatic BD-IPMN without mural nodules, no 
main duct involvement, and a size less than 30 mm can 
be followed up.  Serous cystadenomas carry a very small 
malignant risk and are usually resected only if they 
cause symptoms.  This review article highlights the 
common characteristics and recommended management 
of these cystic lesions of the pancreas.  
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Introduction 
Cystic lesions of the pancreas (CLP) are relatively 
common and with the increasing use of high resolution 
computed tomography (CT) and magnetic resonance 
imaging (MRI) are being increasingly detected.  The 
prevalence of CLP in autopsy series was as high as 24% 
1 and high resolution CT identified these lesions in 2.6% 
of asymptomatic adults and in 8% of patients older than 
80 years.2-3 
 
 
 
 
 
 
 
Pancreatic cystic lesions include serous cystic 
adenomas (SCA), mucinous cystic neoplasms (MCN), 
intraductal papillary mucinous tumors (IPMN), solid 
pseudopapillary tumors (SPN), (which together 
represent 95% of all CLP) and also less 
common lesions such as cystic endocrine tumors and 
lymphangiomas.  Distinguishing between these PCLs is 
extremely important because while some lesions are 
completely benign, other pancreatic cysts carry a 
significant premalignant potential and require close 
follow up or early surgical resection.  In this review 
article, we describe the common characteristics and 
management of the most common pancreatic cystic 
lesions. 
The prevalence of pancreatic cystic lesions appears 
to increase with age. In most cases, cystic lesions are 
detected incidentally by CT or MRI performed for other 
reasons. MRI/magnetic resonance 
cholangiopancreatography (MRCP) and endoscopic 
ultrasound (EUS) are considered to be complementary 
diagnostic tools. The added advantage of EUS is that in 
doubtful cases, cyst fluid analysis may be performed by 
carrying out a fine needle aspirate of the cyst contents. 
MRI should always be carried out before EUS as it 
identifies the number of cystic lesions (which may be 
multiple in IPMN), the relation of the cysts to the main 
pancreatic duct, and the size of the lesions. EUS is 
however superior in evaluating mural nodules (i.e. 
intracystic nodules arising from the cystic wall lining – 
these nodules are frequently precursors of malignant 
transformation and are an indication for surgical 
resection).4 
The premalignant risk of CLP varies according to 
the type of lesion.  While main duct-IPMN and MCN 
carry a significant premalignant risk, SCA are 
considered to have a very low risk of malignant 
transformation.  A recent study by Rhim et al5 has 
shown that patients with CLPs already have pancreatic 
cancer cells in their circulation before pancreatic 
tumours actually develop.  In this study, 
circulating pancreas epithelial cells (CECs) in patient 
blood samples were detected and quantified. The authors 
identified >3 CECs/ml in 7 of 21 patients (33%) 
with CLP (predominantly IPMN) and no clinical 
diagnosis of cancer, in 8 of 11 patients (73%) with 
pancreatic adenocarcinoma, and in 0 of 19 patients 
without cysts or cancer (controls).  This technique may 
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in the future be used in risk assessment of CLPs.5 
 
Intraductal Papillary Mucinous Neoplasms (IPMN) 
IPMN are more commonly found in the head of the 
pancreas (70%) with an equal gender distribution.  They 
are commoner in the 6th and 7th decade and can be 
subclassified into main duct (MD)-IPMN and branch 
duct (BD)-IPMN based on imaging results and 
histology.  All IPMNs appear to communicate with the 
main pancreatic duct and may be multifocal. Dilatation 
of the main pancreatic duct to >5mm on CT or MRI 
(without other causes of obstruction) suggests the 
presence of main duct IPMN with a main duct diameter 
of 5-9mm  being  considered  a  “worrisome  feature”  while  
a   duct   of   1cm   or   more   is   considered   a   “high-risk 
stigmata”.      The   presence   of   a  mucinous   cyst   >5mm   in 
diameter communicating with the main duct without 
causing main duct dilatation is strongly suggestive of 
branch duct IPMN.  Mixed type IPMN have the criteria 
for both MD-IPMN and BD-IPMN.  The difference 
between the two subtypes can be confirmed using EUS 
or intraductal ultrasonography.  If these techniques are 
not available, histological analysis of surgically resected 
specimens can also distinguish between the two.6  
MD-IPMN carries a very high risk of malignant 
transformation (57-92%)7-15 while the risk with BD-
IPMN is somewhat lower (6-46%).7-14 MRI has a better 
sensitivity than CT scan in the detection of CLPs (19.9% 
versus 2.6%)2,16 and for this reason is usually preferred 
in the classification of these lesions.  In small cysts 
(<10mm in diameter), MRI follow up after 2-3 years is 
recommended.  For cysts >10mm in diameter, pancreatic 
CT or gadolinium-enhanced MRI with MRCP are 
recommended, though MRI is better in identifying 
septae, nodules and duct communications.17 
The 2012 international consensus guidelines for 
the management of IPMN 6 recommend that patients 
with  “high-risk  stigmata”  on  CT  or  MRI  should  undergo  
immediate surgical resection without further testing.  
These   “high-risk   stigmata”   include   obstructive   jaundice  
in a patient with a CLP of the pancreatic head, 
enhancing solid component in the cyst and a main duct 
diameter  >10mm.      “Worrisome   features”   include   cystic  
lesion >3cms in diameter, thickened enhanced cystic 
walls, main duct diameter 5-9mm, non-enhanced mural 
nodules, abrupt change in main pancreatic duct diameter 
with distal pancreatic atrophy and the presence of 
lymphadenopathy.18-22 
These patients should be further evaluated with 
EUS, which further risk-stratifies the IPMN.  In the 
presence of a definite mural nodule, if the main duct 
appears dilated or involved during EUS or if fine needle 
aspirate cytology from the cystic fluid is suspicious or 
positive for malignancy, the patient should be referred 
for surgery.  In the absence of these features, follow up 
will depend on the size of the lesion.  For cysts 1-2cms 
in diameter, yearly CT or MRI for 2 years with 
lengthening of the imaging interval if the cyst remains 
unchanged is recommended.  For lesions which are 2-
3cms in diameter, the guidelines recommend 3-6 
monthly EUS with lengthening of the interval, 
alternating with MRI if there is no change.  For cysts 
larger than 3cms, alternating MRI with EUS every 3-6 
months is recommended.  In young fit patients with 
cysts >2cms, surgery may be recommended early to 
avoid prolonged surveillance. 
 
Figure 1: 
a). Endoscopic ultrasound view of a 22 mm branch duct IPMN in the head of the pancreas with no mural nodules and a 
small (<1cm), insignificant peripancreatic lymph node (arrow).   
b). EUS-guided fine needle aspiration (FNA) of cystic fluid for biochemical and cytological analysis; arrow shows needle 
passing through pancreatic parenchyma into the IPMN. 
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The main advantage of EUS over other imaging 
modalities lies in its ability to detect mural nodules and 
invasion, and is most effective in delineating the 
malignant characteristics of these lesions.  In addition, it 
allows the acquisition of cystic fluid for cytological 
assessment and biological analysis of carcinoembryonic 
antigen (CEA) and amylase levels (Figure 1).23-25  
Elevated CEA (>192 ng/mL) is 80% accurate for the 
detection of mucinous cysts, though it provides no clue 
to the risk of malignancy.23,24,26  Cyst amylase levels are 
not uniformly elevated in IPMNs 
Molecular analysis of cyst fluid for KRAS (Kirsten 
Rat Sarcoma) mutations is still mainly an investigational 
tool; however KRAS mutations in cyst fluid are more in 
keeping with a mucinous rather than a malignant cyst.27-
29 In a study analysing sensitivity and specificity of 
KRAS mutation in identifying mucinous differentiation, 
KRAS had a specificity of 100% and sensitivity of 54% 
for mucinous differentiation.  When stratified according 
to cyst type, KRAS had a sensitivity of 67% for IPMNs 
and 15% for MCNs.30  New FNA/B (fine needle 
aspirate/biopsy) needles are now also able to obtain a 
histological sample of the pancreatic cyst wall providing 
higher diagnostic yields of cyst type than standard 
needles.31 
 
Serous Cystadenomas (SCA) 
SCA represent 10-45% of all PCL and are much 
commoner in women (70%).  They are more common in 
the body or tail of the pancreas (>80%) and they do not 
communicate with the pancreatic duct.32 They may be 
either polycystic (microcystic), or oligocystic 
(macrocystic).  Typically they present as single lesions 
with central calcification (in 20%) and high vascularity 
at EUS. If the diagnosis is still not clear, EUS-FNA may 
be used for biochemical assessment (Figure 2).  SCA 
typically have low levels of both CEA (<5 ng/mL) and 
amylase and carry a very small risk of malignant 
transformation (3%).  
Serous microcystic adenomas are glycogen-rich 
cystadenomas surrounded by fibrous capsules which 
separate them from normal tissue.  CT or MRCP can 
frequently distinguish SCA from BD-IPMN because of 
their polycystic or honeycomb pattern. In their interior 
they form a honeycomb appearance with numerous 
small, closely packed cysts arranged around a central 
stellate, calcified scar.33  Serous macrocystic adenomas 
are much less common and consist of fewer, larger cysts, 
typically >1cm in diameter.34  They are more common in 
the pancreatic head and in view of their size may present 
with obstructive jaundice.  Serous macrocystic 
adenomas may be associated with von Hippel Lindau 
disease.35  In view of their small risk of malignant 
transformation, small (<4cms) asymptomatic SCA 
should undergo periodic follow up while larger, 
symptomatic cysts should be resected. 
Figure 2: Endoscopic ultrasound view of a 17mm serous 
cystadenoma in the tail of the pancreas; note the 
honeycomb appearance with multiple small, closely 
packed cysts arranged around a central, calcified scar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mucinous Cystic Neoplasm (MCN) 
MCN include mucinous cystadenomas and 
mucinous cystadenocarcinomas and account for 10% of 
PCLs.  They are much commoner in women (>95%) and 
are more prevalent in the 4th and 5th decades.  MCN are 
usually found as a single lesion in the body or tail of the 
pancreas and they do not usually communicate with the 
main pancreatic duct. At EUS-FNA, MCN amylase 
levels may be increased and CEA level is almost always 
increased.  All young and fit patients with MCN should 
undergo surgical resection because of the elevated risk 
of malignant transformation and the need for prolonged 
surveillance.  In a large series, up to 10% of MCN had 
invasive cancer at the time of resection.36 MCNs <4cms 
in diameter have 15% risk of malignant transformation 
and such lesions may be followed up conservatively in 
elderly or frail patients.6  
 
Solid Pseudopapillary Neoplasm (SPN) 
SPN represent 10% of all PCLs, and are 
predominantly found in young women.  They may occur 
anywhere in the pancreas and may occasionally be very 
large.  At EUS, these lesions may appear solid or mixed 
solid and cystic, with or without septations.  SPN 
frequently undergo central haemorrhagic cystic 
degeneration with a pseudocapsule which may calcify.37 
 They have an indolent course but if left untreated, 
they may invade into adjacent organs and major 
vessels.38 These tumors are usually very slow growing 
and carry an excellent prognosis once resected.  
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Synchronous or metachronous malignant disease in 
extrapancreatic organs 
Synchronous or metachronous malignancy in 
extrapancreatic organs occurs in 20-30% of patients with 
IPMN. Extrapancreatic malignancies appear to occur in 
different organs depending on the incidences of cancer 
in the general populations in different geographical 
regions.39 While there are no current recommendations 
to screen extrapancreatic organs in patients with IPMN, 
a reasonable practice would be to carry out serum 
prostate specific antigen (PSA) assessment, 
mammography and colonoscopy in patients with these 
PCL.  
 
Conclusion 
With the widespread use of abdominal imaging, 
PCLs are increasingly being recognised.  In view of the 
premalignant potential associated with some of these 
lesions, they need to be accurately classified and 
followed-up or resected accordingly.  MCN, SPN, MD-
IPMN and BD-IPMN with "high-risk stigmata" for 
malignancy should be resected while asymptomatic BD-
IPMN without mural nodules, no main duct 
involvement, and a size less than 30 mm can be followed 
up with a watchful waiting strategy. 
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